SAN DIEGO, July 10, 2017 /PRNewswire/ -- HUYA Bioscience International, the leader in accelerating global development ofChina's pharmaceutical innovations, today announced a strategic collaboration agreement with Suzhou BioTOP Technical Service Co., Ltd. (referred to as BioTOP). The collaboration will focus on promoting the development
HUYA is the first company to have recognized China's potential as an important source of new innovative preclinical and clinical stage compounds. The company accelerates the development and value creation for China-sourced novel biopharmaceutical compounds in worldwide markets. HUYA has already established over one hundred collaborations with leading universities and research institutes throughout China as a pioneer in licensing both preclinical and clinical stage compounds.
BioTOP, located in Suzhou BioBay, is a wholly state-owned subsidiary of BioBay. BioTOP endeavors to provide comprehensive and attentive services to innovative companies in life sciences. With its integrated software and hardware service platforms, BioTOP helps companies in BioBay to reduce R&D cost and accelerate the transformation and commercialization processes of R&D accomplishments.
The agreement combines the expertise of both HUYA and BioTOP to promote biomedical innovations with global market potential in the Yangtze River Delta region. Local pharmaceutical companies and research organizations in BioBay will have opportunities to access HUYA's international pharmaceutical knowledge and network resources, as well as the HUYA team's expertise in drug development and commercialization. In return, HUYA will have priority to evaluate certain research and development opportunities of these entities, and potentially co-develop them for global markets in the future.
"This partnership is an exciting strategic step given the knowledge sharing and synergies it will create between HUYA and BioTOP. Such cooperation will not only increase business opportunities for both sides, but also advance the development and globalization of East China's pharmaceutical innovation," said Clement Gingras, HUYA's Chief Technology Officer and Chief Operating Officer Asia.
General Manager of BioTOP, Yongmei Li, also expressed confidence in this collaboration. "The rich resources of science and technology in Yangtze River Delta and the comprehensive services provided by BioTOP in early new drug development, combined with HUYA's expertise in global development of innovative drugs will generate significant advantages to help many resident companies in BioBay that develop innovative drugs. We anticipate more new drug opportunities progressing towards global markets through this collaboration platform," said Ms. Li.
About HUYA Bioscience InternationalHUYA Bioscience International is the leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. Extensive collaborations have been established with innovators to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for maximizing the value of biopharmaceutical innovation in China. HUYA's lead immuno-oncology product HBI-8000 is in registration trials in Japan for lymphoma and in clinical development in the U.S. for solid tumor indications. With the largest team of scientists working with Chinese innovators, HUYA develops promising drug candidates globally. For more information, please visit www.huyabio.com.
About BioTOP and BioBayBioTOP Technical Service Co., Ltd., located in Suzhou BioBay, is a wholly state-owned subsidiary of BioBay, managing all the public platforms of BioBay. BioTOP provides analyses of drug and health product ingredients, GMP verification, supply chain management, technology training, biomaterial express and incubation for startups in life science. The primary mission of BioTOP is to become a one-stop life science partner of enterprises. For more information, please visit http://www.biotop.com.cn/?2.
Suzhou BioBay is located in southwest of Suzhou Industrial Park (SIP), and is the key driver of life science innovation for SIP. More than 400 high-tech innovative companies covering drug discovery, medical device (including IVD), and biotechnology are located in BioBay, and more than 10000 scientists and professionals have come to join this dynamic innovative community. For more information, please visit http://en.biobay.com.cn .
Contact Details:Clement GingrasCTO and COO AsiaHUYA Bioscience International+1 [email protected]
Yung-Chih Wang, PhD, MBAVP, Corporate Development ChinaHUYA Bioscience [email protected]
View original content:http://www.prnewswire.com/news-releases/huya-bioscience-international-establishes-strategic-partnership-with-suzhou-biotop-300485042.html
SOURCE HUYA Bioscience International
Subscribe to our Free Newsletters!
The state health insurance programs provide health care support to the below poverty line (BPL) ...
There is a lining between the lungs and chest wall known as Pleura. The dismissal of pleura by a ...
Reflux nephropathy is the scarring and damage caused to the kidneys by reverse flow of urine from ...View All